Rational approach to selection of antihypertensive therapy in persons with metabolic syndrome: Efficacy of monotherapy with spirapril and its combination with retard form of nifedipine

Kardiologiya

Volumn 46, Issue 9, 2006, Pages 26-30

  Mamedov, M N ^a   Kiseleva, N V ^a  

^a NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

Author keywords

Metabolic syndrome; Nifedipine; Spirapril

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; ENALAPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; SPIRAPRIL;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; GLUCOSE INTOLERANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIFEDIPINE; SEVERITY OF ILLNESS INDEX;

EID: 33750272011     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ferrannini E., Natali A., Capaldo B. et al. Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European Group for the study of insulin Resistance (EGIR). Hypertension 1997;30:1144-1149.
2. Standl E. Aetiology and consequences of the metabolic syndrome. Eur Heart J 2005;7:D:10-13.
3. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
4. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
5. Mule G., Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich) 2006;8:3:195-201.
6. Valensi P. All in one. Monde Moderne (France) 2004;71-110, 184-209.
7. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabet Care 2004;27:6:1487-1495.
8. Vreugdenhil G., van Montfrans G.A., Jacobs M.C. et al. Blood Press 1994;2:3:23-30.
9. Otterstad J.E. et al. Blood Press 1994;322:1561-1566.
10. Zannad F. et al. Am J Hypertens 1996;9:7:633-643.
11. Nayler W. Amlodipine, An Overwiew. Clin Drug Invest 1997;13: Suppl 1:1-11.